跗前与隔前联合肉毒毒素注射治疗眼睑痉挛:一项前瞻性非随机临床试验
该前瞻性非随机临床试验在45例良性特发性眼睑痉挛患者中比较了跗前联合隔前注射与常规跗前注射肉毒毒素的疗效,共95次注射。联合注射组起效和达峰更短、峰效应和总应答持续时间更长、满意度更高,仅1例出现上睑下垂,其他并发症无显著差异。
要点
- 联合注射组起效时间4.00天 vs 常规组5.00天(P=.024),达峰时间23.50天 vs 26.00天(P=.040)。
- 联合注射组峰效应持续时间88.00天 vs 常规组75.00天(P=.003),总应答持续时间135.00天 vs 121.00天(P=.003)。
- 联合注射组满意度9.50 vs 常规组8.00(P<.001),约2/3患者更愿意以后接受联合注射。
核心结论
- 跗前联合隔前注射肉毒毒素在疗效和患者满意度方面均优于常规跗前注射。
研究设计与样本
- 前瞻性非随机临床试验,2023年1月至2024年4月纳入45例良性特发性眼睑痉挛患者,共行95次眼轮匝肌肉毒毒素注射,其中联合注射52次、常规跗前注射43次。
- 采用Jankovic评定量表和眼睑痉挛残疾指数评估运动症状。
主要发现
- 两种注射方法均显著改善良性特发性眼睑痉挛患者的Jankovic评定量表和眼睑痉挛残疾指数评分。
- 联合注射组起效时间4.00(3.00,6.00)天 vs 常规组5.00(4.00,7.00)天,P=.024;达峰时间23.50(16.00,26.00)天 vs 26.00(20.00,30.00)天,P=.040。
- 联合注射组峰效应持续时间88.00(80.50,104.75)天 vs 常规组75.00(65.00,92.00)天,P=.003;总应答持续时间135.00(118.50,153.75)天 vs 121.00(107.00,135.00)天,P=.003。
- 联合注射组满意度9.50(8.50,10.00) vs 常规组8.00(7.50,9.00),P<.001;约2/3患者更愿意以后接受联合注射。
- 联合注射组仅1例出现上睑下垂,流泪、干眼和视物模糊等其他并发症在两种方法间无显著差异。
临床怎么用
- 作者结论认为跗前联合隔前注射肉毒毒素在疗效和患者满意度方面较常规跗前注射更具优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy of two botulinum toxin (BoNT) injection methods, pretarsal (PT) combined with preseptal (PS) injection (PT-PS) and conventional PT injection, in the treatment of benign essential blepharospasm (BEB). DESIGN: Prospective nonrandomized clinical trial. METHODS: From January 2023 to April 2024, 95 BoNT injections into orbicularis oculi were performed in 45 BEB patients, including 52 PT-PS injections s and 43 PT injections. Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI) were used to assess motor symptoms. The efficacy of two injection methods for BEB was compared in terms of latency to response (LTR), latency to the peak response (LPR), duration of peak response (DPR), duration of response (DOR), satisfaction degree, and possible complications. RESULTS: Both injection methods significantly improved JRS and BSDI scores in patients with BEB. However, PT-PS injections showed a shorter LTR ([4.00 (3.00, 6.00] vs 5.00 [4.00, 7.00] days, P = .024) and LPR (23.50 [16.00, 26.00] vs 26.00 [20.00, 30.00] days, P = .040), a longer DPR (88.00 [80.50, 104.75] vs 75.00 [65.00, 92.00] days, P = .003) and DOR (135.00 [118.50, 153.75] vs 121.00 [107.00, 135.00] days, P = .003) than PT injections. Patients with PT-PS injections were more satisfied than those with PT injections (9.50 [8.50, 10.00] vs 8.00 [7.50, 9.00], P < .001), and around 2/3 of patients were more willing to receive the combined injection method later. Among patients receiving PT-PS injections, only one case experienced ptosis, and there were no significant differences in other complications such as lacrimation, dry eyes, and blurred vision between the two injection methods. CONCLUSIONS: PT-PS injections of BoNT showed more advantages in the treatment of BEB than PT injections in terms of both their efficacy and patients' satisfactions.
引用
- Hu J, Mu Q, Ma F, et al. Combination of Pretarsal and Preseptal Botulinum Toxin Injections in the Treatment of Blepharospasm: A Prospective Nonrandomized Clinical Trial. Am J Ophthalmol. 2024. PMID: 39424025. doi:10.1016/j.ajo.2024.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。